Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib

Authors:

Abstract
Gastrointestinal stromal tumors (GISTs) arise predominantly in the muscularis mucosa of the gastrointestinal tract, of which most contain activating mutations in V-Kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog (KIT) (OMIM 164920), which encodes a transmembrane tyrosine kinase. A few GISTs (5%-10%) contain activating mutations in the platelet-derived growth factor receptor α (PDGFRA) (OMIM 173490) gene; the most common PDGFRA mutation is in exon 18, resulting in a change in residue 842 from aspartic acid to valine (D842V).1,2 Those GISTs that lack mutation in KIT or PDGFRA frequently have loss of the succinate dehydrogenase (SDH) complex through mutation of a gene that encodes 1 of the subunits or epigenetic regulation that affects gene expression.3 The initial treatment for patients with unresectable, recurrent, or metastatic GISTs is imatinib mesylate based on drug activity, drug tolerability, and long-term control of GISTs in randomized clinical trials.4-6 Patients with GISTs that are primary refractory to imatinib frequently have mutations in KIT or PDGFRA within an exon that renders the protein less sensitive to inhibition of kinase activity by imatinib or unmutated (wild-type) KIT and PDGFRA.1 In patients whose GISTs initially respond to imatinib but later progress during treatment, secondary mutations in KIT frequently occur and contribute to the development of resistance.7

This publication has 29 references indexed in Scilit: